Terms: = Prostate cancer AND SMARCD1, CRACD1, 6602, ENSG00000066117, Rsc6p, BAF60A, Q96GM5 AND Treatment
3 results:
1. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in prostate cancer: Results From the DART 01/05 Randomized Phase 3 Trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; González-San Segundo C; Cabeza Rodriguez MA; Macías V; Pedro Olive A; Casas F; Boladeras A; Martín de Vidales C; Vázquez de la Torre ML; Calvo FA
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):341-348. PubMed ID: 27598804
[TBL] [Abstract] [Full Text] [Related]
2. Association of Survival Benefit With Docetaxel in prostate cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
de Morrée ES; Vogelzang NJ; Petrylak DP; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; Ochoa de Olza M; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; Li JS; de Wit R
JAMA Oncol; 2017 Jan; 3(1):68-75. PubMed ID: 27560549
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers.
Rane JK; Erb HH; Nappo G; Mann VM; Simms MS; Collins AT; Visakorpi T; Maitland NJ
Oncotarget; 2016 Aug; 7(32):51965-51980. PubMed ID: 27340920
[TBL] [Abstract] [Full Text] [Related]
